Preimmunization correlates of protection shared across malaria vaccine trials in adults

Maxwell L. Neal, Fergal J. Duffy, Ying Du, John D. Aitchison and Kenneth D. Stuart

Identifying preimmunization biological characteristics that promote an effective vaccine response offers opportunities for illuminating the critical immunological mechanisms that confer vaccine-induced protection, for developing adjuvant strategies, and for tailoring vaccination regimens to individuals or groups. In the context of malaria vaccine research, studying preimmunization correlates of protection can help address the need for a widely effective malaria vaccine, which remains elusive. In this study, common preimmunization correlates of protection were identified using transcriptomic data from four independent, heterogeneous malaria vaccine trials in adults. Systems-based analyses showed that a moderately elevated inflammatory state prior to immunization was associated with protection against malaria challenge. Functional profiling of protection-associated genes revealed the importance of several inflammatory pathways, including TLR signaling. These findings, which echo previous studies that associated enhanced preimmunization inflammation with protection, illuminate common baseline characteristics that set the stage for an effective vaccine response across diverse malaria vaccine strategies in adults.

npj Vaccines (2022) 7:5; https://doi.org/10.1038/s41541-021-00425-1

INTRODUCTION

Whether a vaccine generates an immune response that results in protection from infection or disease depends in part on the preimmunization status and capacities of the vaccinated individual's immune system. Identifying preimmunization correlates of protection, therefore, offers opportunities for illuminating the immunological pathways that promote or attenuate protective vaccine responses, for identifying avenues whereby the immune system can be influenced to respond effectively, and for developing personalized approaches that predict vaccine efficacy on an individual or group basis. These opportunities can potentially benefit malaria vaccine development efforts: Although substantial progress has been made developing anti-malaria vaccines, a vaccine that is widely effective has remained elusive, and it remains unclear why malaria vaccines induce a protective response in some individuals but not in others. Exploring the preimmunization correlates of protection in malaria vaccine trials presents an opportunity to identify the immunological conditions that set the stage for vaccine-induced responses that are protective against future infection and to help guide the rational design of more effective vaccines. While the list of studies in this research area is not extensive, some preimmunization correlates of protection have been identified for vaccines against influenza, hepatitis B, yellow fever, and malaria.

To identify common preimmunization correlates of protection across various malaria vaccine trials, we performed transcriptomic analysis of four independent trials: the Immunization via Mosquito Bite with Radiation-Attenuated P. falciparum Sporozoites (IMRAS) trial, the Bagamoyo SporoZoite Vaccination 1 (BSPZV1) trial, the MAL68 RTS,S vaccine trial, and a Chloroquine Prophylaxis and Sporozoites (CPS) trial. These trials varied in the vaccines administered (live, radiation-attenuated whole sporozoites, RTS,S subunit vaccine or live sporozoites where establishment of blood stage infection was prevented by chloroquine chemoprophylaxis), the route of administration (intravascular injection, intramuscular injection, or mosquito bite) the country of trial subject recruitment (USA, Tanzania, or The Netherlands), whether subjects were malaria-naïve prior to immunization (USA, The Netherlands) or experienced (Tanzania), and the source of transcriptomic material (whole blood or peripheral blood mononuclear cells—PBMCs). Each trial included a challenge phase, wherein subjects were infected with infectious P. falciparum to determine whether the subject mounted a vaccine response protective against malaria. Despite the wide-ranging clinical trial conditions, our results indicate that protection against post-immunization malaria challenge is associated with innate immune system activation and a moderately elevated inflammatory state prior to immunization, including higher expression in genes associated with TLR signaling and other inflammatory pathways. These results echo molecular- and pathway-level preimmunization correlates of malaria protection derived from previous analyses on narrower sets of clinical trials. They highlight specific immunological pathways that may play critical roles in the development of effective malaria vaccine-elicited responses and offer potential targets for manipulating the immune system into a state that promotes such responses.

RESULTS

Correlates of protection among pooled preimmunization transcriptomes

Preimmunization transcriptomes were pooled from the four malaria vaccine trials and consisted of 84 samples (Table 1, Methods). A differential expression analysis comparing the transcriptomes of all protected participants (n = 38) and all non-protected participants (n = 46) pooled from the trials revealed no genes with statistically significant differences in transcript abundance using an FDR-adjusted P-value cutoff of 0.1. To test
## Table 1. Characteristics of the four clinical trials that generated transcriptomic data used to identify preimmunization correlates of protection.

|                          | IMRAS                                                                 | BSPZV1                                      | MAL68          | CPS                       |
|--------------------------|------------------------------------------------------------------------|---------------------------------------------|----------------|---------------------------|
|                          | Immunization via Mosquito Bite with Radiation-Attenuated P. falciparum Sporozoites | Bagamoyo SPoroZoite Vaccination 1          |                |                           |
| ClinicalTrials.gov ID    | NCT01994525                                                            | NCT02132299                                 | NCT01366534    | NCT01218893               |
| Immunogen                | Radiation-attenuated sporozoites via mosquito bite                      | Radiation-attenuated sporozoites via IV injection |                |                           |
| Recruitment country      | U.S.A.                                                                 | Tanzania                                    | U.S.A.         | The Netherlands           |
| Sample source            | Whole blood                                                            | Whole blood                                 | PBMCs          | Whole blood               |
| N preimmunization samples| 11                                                                     | 22                                          | 45             | 7                         |
| Prior malaria exposure   | Naive                                                                  | Non-naive                                   | Naive          |                           |
| N female/male            | 1 / 10                                                                 | 0 / 22                                      | 20 / 25        | 3 / 4                     |
| N challenge-protected/   | 6 / 5                                                                  | 8 / 14                                      | 21 / 24        | 3 / 4                     |
| non-protected            |                                                                        |                                             |                |                           |
| Sequencing system        | Illumina HiSeq 2000                                                    | Illumina HiSeq 4000                         | Illumina HiSeq 2000 | Illumina NextSeq 500     |
| Paired-end or single-read| Paired-end                                                             | Paired-end                                  | Paired-end     | Paired-end                |

To identify differences at the level of gene sets, we then performed the same type of GSEA as performed with the pooled samples. From the GSEA results on each trial (Supplementary Fig. 1), we then identified gene sets that showed significant positive enrichment scores consistently across all trials or consistently showed significant negative scores. Despite substantial differences in the gene sets associated with protection in each trial, we identified fourteen gene sets showing directionally consistent, significant enrichment for genes with higher transcript abundance in protected subjects across trials, and two sets showing directionally consistent, significant enrichment for transcripts with lower abundance in protected subjects across trials (Fig. 3).

The 14 gene sets showing consistently higher transcript levels in protected subjects prior to immunization were predominantly associated with inflammatory and inflammatory signaling pathways, myeloid lineage cells including monocytes and neutrophils, coagulation, antigen presentation, cell death and apoptosis, the endoplasmic reticulum, the extracellular matrix, and the complement system (Fig. 1). Gene sets enriched for lower abundance transcripts in protected subjects were predominantly associated with the cell cycle, protein synthesis, interferon, T cells, mitochondria stress/respiration, and NK cells. As illustrated in Fig. 2, leading-edge genes (those primarily responsible for the significant enrichment scores due to non-random grouping at the tails of a ranked list) from gene sets with the highest and lowest normalized enrichment scores (NESs) showed moderate differences in transcript abundance between protected and non-protected subjects. For example, the top 10 leading-edge genes in Fig. 2a showed a mean log2 fold-change of 0.41 ± 0.22 (SD) between protected and non-protected subjects. Our analysis revealed that, when comparing protected and non-protected subjects, differences in transcript abundance of gene sets showed statistical significance, whereas differences at the individual gene level did not.

### Correlates of protection shared across individual trials

The analyses on the pooled set of preimmunization transcriptomes include all samples aggregated across all four trials. To perform a more conservative analysis that limits correlates driven primarily by individual trials, we computed differential expression and performed GSEA for each trial separately, then identified genes and gene sets that consistently showed significant differences between protected and non-protected subjects across trials. As with the differential expression analysis on the pooled transcriptomes, the number of transcripts showing significant differences in abundance between protected and non-protected subjects was low in each trial ($N = 2$ for IMRAS, $N = 0$ for BSPZV1 and MAL68, $N = 14$ for CPS; FDR-adjusted $P$-value < 0.1).

To identify pathways of leading-edge genes common across trials. While the gene sets used in our GSEA analysis are useful for characterizing gene groups according to their more general biological functions, they do not represent specific mechanistic molecular pathways. To identify such pathways that were consistently associated with protection at the preimmunization timepoint, we performed an Ingenuity Pathway Analysis (IPA) on the set of common leading-edge gene sets collected from the gene sets in Fig. 3 that showed directionally consistent, significant enrichment across vaccine trials. For each of these 16 functional gene sets, we collected the genes that appeared as GSEA leading-
Discriminatory power of protection-associated genes and gene sets. The protection-associated genes and gene set common across trials suggest there are transcriptomic features that might be used in classifiers that discriminate, on an individual basis, which vaccinees will mount a protective immune response to immunization and which will not. To assess the discriminatory power of these features, we developed and tested various scores based on transcript abundances (counts per million) of the 98 protection-associated, leading-edge genes described above as well as mean transcript levels corresponding to those genes within protection-associated gene sets. We also tested the discriminatory power of scores based on transcript abundance ratios between protection-associated genes and between gene sets. For all scoring strategies, individual scores were computed for each trial participant based on their preimmunization transcriptomic profile. We then assessed the discriminatory power of the score by varying the threshold used to classify individuals as protected or non-protected and then generating a receiver operating characteristic (ROC) curve from the sensitivity and specificity of the score. The discriminatory power of the score was assessed using the area under the ROC curve (AUC). We found that the AUC for the protection-associated gene sets was significantly higher than that for random gene sets, indicating that protection-associated gene sets have higher discriminatory power than random gene sets.
GSEA normalized enrichment scores for each gene set in each trial. In protected subjects across malaria vaccine trials. Enrichment for gene transcripts with higher or lower abundance in subjects pooled from four malaria vaccine trials. a Transcript abundance in counts per million (CPM) for the top ten leading-edge genes in DC.M3.2 Inflammation, the gene set showing the highest significant normalized enrichment score in the GSEA analysis (indicating significantly higher abundances in protected subjects). b Transcript abundance for the top ten leading-edge genes in LI.M4.1 cell cycle (I), the gene set showing the lowest significant normalized enrichment score in the analysis (indicating significantly lower abundances in protected subjects).

**DISCUSSION**

Our findings indicate that a moderately elevated preimmunization inflammatory state, as revealed by RNA-seq transcriptomic measurements on whole blood or PBMCs, is associated with a protective response to malaria challenge following a variety of immunization strategies in adults. A heightened preimmunization inflammatory state has previously been linked to vaccine-induced protection against influenza in non-elderly adults, and our results also link this finding to the malaria vaccination strategies analyzed here. Our findings contrast with studies investigating correlates of protection following hepatitis B immunization where innate immune activation prior to immunization has been linked to non-protection in adults.

Across the four trials we analyzed, transcripts from several inflammatory and innate response gene sets trended higher in protected subjects, and this trend was significant when treating gene sets as the unit of analysis. Analyses at the level of individual transcripts did not reveal significant differences between protected and non-protected subjects across trials. Thus, the expression differences we observed between these groups link protection to a moderately higher activation of inflammatory and innate response processes. While moderate, these differences are, collectively, substantial enough to have potential utility in metrics that predict whether an individual subject will mount a protective vaccine response prior to immunization. The best-performing preimmunization score we found for discriminating protected and non-protected subjects incorporated transcript abundance information from 15 genes, outperforming scores based on single genes. While the discriminatory performance of this score was similar across individual trials, its performance in the BSPZV1 trial was the poorest. BSPZV1 was unique among the trials analyzed in that its participants were not malaria-naive and the immunization used cryopreserved radiation-attenuated sporozoites delivered intravenously. The poorer performance of our score for this trial may have been due to one or both of these factors or other trial-specific characteristics. Further studies with additional data sets will be needed to determine which trial characteristics led to a poorer predictive performance. Such studies might reveal correlates of protection unique to the non-naive clinical group, which might be used in combination with the common correlates of protection we identified to generate specialized, predictive scores that perform better for non-naive individuals than more general-purpose scores. Similar studies might identify correlates of protection that are unique to other
These results echo previous findings by Moncunill, et al. who identified TLR4 as a member of several gene signatures predictive of protection in RTS,S-vaccinated children. These signatures were derived from expression changes in preimmunization PBMCs that were stimulated with CSP and/or P. falciparum-infected erythrocytes. Their results suggested that higher preimmunization TLR4 expression may help the immune system respond more effectively to the RTS,S vaccine. As noted by these authors, the LPS-derived chemical monophosphoryl lipid A (MPL) used as an adjuvant in combination with the subunit RTS,S vaccine is a TLR4 agonist. Our results, which link higher preimmunization expression of TLR1, TLR4 and TLR8 to protection, also suggest a role for TLR agonists as adjuvants in the development of a protective vaccine response.

Moncunill et al. also found preimmunization signatures of protection in a separate trial where adults were immunized with fresh sporozoites delivered via mosquito bite under chloroquine prophylaxis. The best-performing preimmunization signature derived from CSP-stimulated PBMCs for this trial linked protection with proinflammatory activity of participants in the canonical and non-canonical NFκB pathways. These pathway participants included CSF2 (also known as GM-CSF), and our IPA Upstream Analysis identified CSF2, RELA, and NFκB complex activation as potential upstream perturbations contributing to the increased expression and transcript abundance differences we observed between protected and non-protected subjects. Also included in the CPS signature is ITGA2, an integrin that contributes to p38 MAPK signaling which in turn controls the activity of the RELA NFκB subunit. The p38 MAPK signaling pathway was also enriched for leading-edge genes associated with protection across trials in our IPA Canonical Pathways analysis (Fig. 4). The leading-edge genes participating in this pathway included CREB5, IL18RAP, IL1RN and IRAK3, all of which showed elevated expression in protected subjects across trials. These results suggest that, although we did not see overlap between our set of 98 leading-edge genes and the genes in the preimmunization signature associated with CSP-stimulation in the chloroquine prophylaxis trial analyzed by Moncunill et al., NFκB-mediated inflammation pathways appear to be a critical determinant of protection in both studies.

An important difference between the Moncunill et al. study and ours is that our transcriptomic measurements were taken from unstimulated tissues and therefore present snapshots of subjects’ preimmunization immunological states whereas the Moncunill, et al. measurements reflect immunological responses to antigen stimulation. Taken together, these results associate protection with an innate immune system that is simultaneously more activated prior to immunization and more capable of responding to immunization. These results may be driven by higher-than-average innate immune functionality in protected subjects or lower-than-average functionality in non-protected subjects, or a combination of both. A recent report by Yap et al. provides evidence suggesting preimmunization correlates of protection may be driven by actively decreased inflammatory functions in non-protected subjects. The authors report that higher baseline expression of T cell inhibitory ligands CTLA-4 and TIM-3 in CD4+ T cells is associated with a “slow-responder” phenotype in adults that is less likely to result in sterile protection following...
immunization via controlled human malaria infection under chloroquine prophylaxis (CHMI-CPS). Increases in these inhibitory ligands can result from mechanisms that protect against inflammation-induced damage (for example in response to chronic parasitemia in malaria-endemic areas). The authors argue that these inhibitory ligands may interfere with NFκB signaling, which is preferentially activated in subjects who mount a protective response to this type of immunization, and this leads to insufficient production of IFN-γ. Rapid induction of IFN-γ following immunization is a characteristic of a “fast-responder” phenotype in CHMI-CPS trials that is more likely to result in sterile protection. Consistent with these findings, our IPA Upstream Analysis identified increased IFN-γ as a perturbation that would generate expression changes consistent with those observed between protected and non-protected individuals. IFN-γ had the highest z-score in this analysis, indicating strong agreement
between a hypothetical increase in IFN-γ and our observed expression patterns showing higher inflammation in protected subjects prior to immunization. Given this consistency between our findings and those of Yap et al., it may be that non-protected individuals in our study had a less successful immunization response due to protective inflammatory inhibition. However, the group of individuals we analyzed was heterogeneous; therefore, we cannot rule out attributing protection to higher-than-average innate responses among protected subjects. Furthermore, these two interpretations are not mutually exclusive: our results may simultaneously reflect immuno-suppressive factors in non-protected subjects and immuno-activating factors in protected subjects.

Children, due to their increased vulnerability to malaria, are the primary target for malaria vaccines, and further studies will be needed to determine whether the preimmunization correlates of protection we identified generalize to younger populations. As mentioned above, preimmunization signatures of protection in children identified by Moncunill et al. included TLR4, which is a participant in many of the pathways associated with protection in our study. This suggests that the pathways critical for mounting an effective malaria vaccine response in adults may be similar to those in children. We also note that all vaccines used in the studies we analyzed target the sporozoite stage and further studies will be needed to generalize our results to malaria vaccines that target other stages.

The results presented here suggest that assessing malaria vaccinee’s preimmunization status may lead to important correlates of protection and tailoring immunization regimens accordingly may emerge as an important element to ensuring a protective response to immunization. Moreover, our results also offer potential pharmacological interventions that may coax an individual’s immune state into one that is primed to respond effectively to immunization.

METHODS
Transcriptomic data sources
Trials selected for use in the study represent all publicly available studies, to our knowledge, that included preimmunization transcriptomics analyzed via RNA-seq to allow a more direct comparison across a wider dynamic range, and which also included an assessment of protection via controlled human challenge with infectious P. falciparum following immunization. Transcriptomic and challenge data were obtained for the IMRAS and BSPZV1 trials through direct collaboration with trial researchers. The MAL68 and CPS trial data are publicly available (see Data availability). The trials, described below, are summarized in Table 1. Each trial investigated a different malaria vaccine candidate and, together, represent adult cohorts from malaria-naive and non-naive populations. From these trials, 85 preimmunization transcriptomic profiles from distinct biological samples were available to investigate correlates of protection.

**Trial 1: IMRAS.** The IMRAS trial[^22] (ClinicalTrials.gov identifier NCT01994525; https://clinicaltrials.gov/ct2/show/NCT01994525) was performed in malaria-naive participants recruited from the United States. The trial assessed the safety, tolerability, and biomarkers of protection of immunization via radiation-attenuated sporozoites delivered by infectious mosquito bites. Preimmunization transcriptomics data were obtained from whole blood samples collected on the day of the first immunization from 11 immunized participants in the trial’s Cohort 1, each of whom received five doses of radiation-attenuated P. falciparum via mosquito bite. Three weeks after the fifth immunization, participants were challenged via P. falciparum-infected mosquito bites. To facilitate the identification of correlates of protection, the IMRAS immunization regimen was designed to achieve ~50% sterile protection in immunized patients: 6 out of the 11 immunized participants (54%) in Cohort 1 were protected following challenge.

**Trial 2: BSPZV1.** The BSPZV1 trial[^23] (ClinicalTrials.gov identifier NCT02132299; https://clinicaltrials.gov/ct2/show/NCT02132299) was performed in male, malaria-exposed recruits from Tanzania. The trial was designed to determine if protective immune responses against P. falciparum infection could be generated in a relatively non-immune population within a malaria-endemic country through immunization with aseptic, cryopreserved, live, radiation-attenuated P. falciparum sporozoites delivered intravenously (IV). Preimmunization transcriptomic data from 22 immunized participants were obtained from whole blood samples collected on the day of the first immunization. Each participant received five immunizations and, three weeks after the last, were challenged with infectious, aseptic, cryopreserved P. falciparum sporozoites delivered IV.

**Trial 3: MAL68.** The MAL68 trial[^24] (ClinicalTrials.gov identifier NCT01366534; https://clinicaltrials.gov/ct2/show/NCT01366534) compared the ability of two malaria vaccination regimens to elicit protection against malaria challenge in malaria-naive recruits from the United States. The study’s first vaccine regimen consisted of three doses of the RTS,S/AS01 vaccine, which combines a recombinant protein-encoding part of the malaria parasite’s circumsporozoite (CSP) protein, the hepatitis B surface antigen, and the AS01 adjuvant. This adjuvant includes the Toll-like receptor 4 (TLR4) agonist 3-O-desacyl-4′-monophosphoryl lipid A (MPL) and the QS-21 saponin[^33]. The second regimen was the same as the first except a different vaccine. Ad35.CS.01, was used for the first immunization. Ad35.CS.01 consists of replication-deficient adenovirus 35 expressing recombinant CSP. Preimmunization transcriptomics from 45 immunized participants (21 from the first regimen, 24 from the second) were obtained from PBMCs collected on the day of the first immunization. Participants were challenged with P. falciparum-infected mosquitoes two weeks following the third immunization.

**Trial 4: CPS.** The CPS trial[^25][^26] (ClinicalTrials.gov identifier NCT01218893; https://clinicaltrials.gov/ct2/show/NCT01218893) investigated the influence of dosing level on the development of protection against malaria challenge when immunizing malaria-naive participants with P. falciparum-infected mosquito bites obtained under chloroquine prophylaxis. Participants were recruited in The Netherlands and received three immunizations separated by 4-week intervals. They were challenged 19 weeks after the last immunization by exposure to bites from five mosquitoes infected with a homologous P. falciparum strain. Preimmunization transcriptomics were obtained from whole blood samples collected one week prior to the first immunization and were from seven members of the study group immunized with 15 mosquito bites total.

Transcriptomic analyses
RNA-Seq FASTQ files were preprocessed to adjust base calls with phred scores <5 to ‘N’. Read pairs for which either end has fewer than 30 unambigous base calls were removed, a method that indirectly removes pairs containing mostly sequencing errors. Read pairs were aligned to the human genome (hg19) using STAR[^34] version 2.3.1d. Gene count tables were generated with HTSeq[^35] version 0.6.0 using the intersection-strict setting and including strand information. Gene annotations used to generate count tables were obtained from the Ensembl database (GRC37.74).

Differential expression analyses comparing preimmunization sample counts from challenge-protected trial subjects to non-protected subjects were performed using DESeq2[^36] version 1.28.0. Principal Component Analysis (PCA) was used to identify outliers among transcriptomic samples: If a sample’s first or second principal component value was more than three standard deviations from the corresponding principal component’s mean, they were excluded from downstream analyses. One sample from the CPS trial was identified as an outlier based on PCA. To account for batch effects among trials, we used a DESeq2 design formula that included a trial term as well as a protected/non-protected classification term. Differential expression analyses performed on samples from the same trial only included the latter term.

Differential gene expression was performed on gene lists ranked by the DESeq2 Wald test statistic using the fgsea package[^37] version 1.140.0 in R. Gene sets used for GSEA were obtained through the tmod R package[^38] version 0.46.2 and the MSigDB Hallmark gene set[^39] download site (http://www.gsea-msigdb.org/gsea/msigdb/genesets.jsp?collection=H). IPA content version 6208961 was used to generate all IPA-based results. ROC analyses were performed using the pROC package[^40] version 1.17.0.1 in R. For all statistical tests, FDR-adjusted P-values (Benjamini-Hochberg method[^41]) <0.05 were considered significant unless otherwise indicated.

All transcriptomic data processing and analyses were performed using publicly available software; no custom algorithms or software packages

---

[^22]: ClinicalTrials.gov identifier NCT01994525
[^23]: ClinicalTrials.gov identifier NCT02132299
[^24]: ClinicalTrials.gov identifier NCT01366534
[^25]: ClinicalTrials.gov identifier NCT01218893
[^26]: ClinicalTrials.gov identifier NCT01218893
played a central role in the study. Supplementary Fig. 2 illustrates the overall analysis pipeline we used in this study to identify preimmunization correlates of protection from raw RNA-seq count data. It also indicates which figures in the manuscript are associated with specific outputs of the pipeline.

Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article.

DATA AVAILABILITY
Transcriptomic data for the IMRAS and BSP2V1 trials will be publicly available through the ImmPort portal (immport.org) under accessions SDY1230 and SDY1742, respectively. Data for the MAL68L and CPS trials are publicly available through Sequence Read Archive BioProjects PRJNA401870 and PRJNA381264, respectively.

Received: 17 August 2021; Accepted: 2 December 2021; Published online: 14 January 2022

REFERENCES
1. Petra, Z. & Nigel, C. Factors that influence the immune response to vaccination. Clin. Microbiol. Rev. https://doi.org/10.1128/CMR.00084-18 (2019).
2. Duffy, P. E. & Patrick Gorres, J. Malaria vaccines since 2000: progress, priorities, products. npj Vaccines https://doi.org/10.1038/s41541-020-0196-3 (2020).
3. RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31–45 (2015).
4. Mwakingwe-Omari, A. et al. Two chemostimulated PFPZ malaria vaccines induce sterile hepatic immunity. Nature 595, 289–294 (2021).
5. Datoo, M. S. et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet 397, 1809–1818 (2021).
6. HIPC-CAY Signatures Project Team & HIPC-I Consortium. Multicohort analysis reveals baseline transcriptional predictors of influenza vaccination responses. Sci. Immunol. https://doi.org/10.1126/sciimmunol.aao4656 (2017).
7. Tsang, J. S. et al. Global analyses of human immune variation reveal baseline predictors of postvaccination responses. Cell 157, 499–513 (2014).
8. Frasca, D. et al. Unique biomarkers for B-cell function predict the serum response to pandemic H1N1 influenza vaccine. Int. Immunol. 24, 175–182 (2012).
9. Kennedy, R. B. et al. The composition of immune cells serves as a predictor of overall analysis pipeline we used in this study to identify preimmunization correlates of protection from raw RNA-seq count data. It also indicates which figures in the manuscript are associated with specific outputs of the pipeline.

ACKNOWLEDGEMENTS
We would like to thank Nana Minkah for helpful discussions regarding preimmunization correlates, and all volunteers who participated in the clinical trials that were analyzed. This work was supported by National Institutes of Health grants U19AI128914 (to K.D.S.) and P41GM109824 (to J.D.A.) as well as Bill & Melinda Gates Foundation grant GHAP NG-ID18-Stuart.

AUTHOR CONTRIBUTIONS
M.L.N. performed all analyses, interpreted findings, and prepared the manuscript. F.J.D. identified and obtained transcriptomic datasets for analysis, generated counts from sequencing data, helped guide analyses, and edited the manuscript. Y.D. generated counts from sequencing data and edited the manuscript. J.D.A. and K.D.S. conceived the study, interpreted findings, and edited the manuscript.

COMPETING INTERESTS
The authors declare no competing interests.
